Agreements reached under this partnership
Business Alliance- 1
We acquired the exclusive rights to market this product in Japan for the treatment of Rett syndrome.
- 2
We will file the application for marketing approval.
- 3
After the product is listed for reimbursement, we will receive product supplies from Acadia Pharmaceuticals and market the product exclusively.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Upon achieving certain net sales targets, we will pay up to US$45 million in milestone payments, among other amounts.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
Already reflected in the full-year consolidated earnings forecast for the fiscal year ending March 2027. The upfront payment is scheduled to be recorded as selling, general and administrative expenses (research and development expenses) in the third quarter of the current fiscal year.
| Item | Details |
|---|---|
| Name of alliance partner | Acadia Pharmaceuticals Inc. |
| Alliance partner's business activities | Development and marketing of treatments for neurological and rare diseases |
| Alliance partner's location | San Diego, United States |
| Type of alliance | Business Alliance |
| Details of the alliance | We acquired the exclusive rights to market this product in Japan for the treatment of Rett syndrome., We will file the application for marketing approval., After the product is listed for reimbursement, we will receive product supplies from Acadia Pharmaceuticals and market the product exclusively. |
| Acquisition price | Upfront payment of US$30 million, plus up to US$45 million in milestone payments, among other amounts |
| Numerical targets under the alliance | Upon achieving certain net sales targets, we will pay up to US$45 million in milestone payments, among other amounts. |
| Alliance start date | Exclusive marketing will begin after the product is listed for reimbursement. The specific date is Not disclosed |
| Impact on Business Performance | Already reflected in the full-year consolidated earnings forecast for the fiscal year ending March 2027. The upfront payment is scheduled to be recorded as selling, general and administrative expenses (research and development expenses) in the third quarter of the current fiscal year. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide valuable new treatments that address unmet medical needs and make new treatment options available as soon as possible. The agreement will also advance the expansion of the development pipeline through proactive in-licensing investments, as set out in the medium-term management plan.